Arecor Therapeutics Future Growth
Future criteria checks 2/6
Arecor Therapeutics's earnings are forecast to decline at 1.8% per annum while its annual revenue is expected to grow at 35.2% per year. EPS is expected to decline by 1.8% per annum.
Key information
-1.8%
Earnings growth rate
-1.8%
EPS growth rate
| Biotechs earnings growth | 37.2% |
| Revenue growth rate | 35.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 12 | N/A | -2 | N/A | 2 |
| 12/31/2025 | 9 | -6 | -3 | -3 | 3 |
| 12/31/2024 | 6 | -8 | -8 | -9 | 3 |
| 6/30/2024 | 5 | -9 | -6 | -6 | N/A |
| 3/31/2024 | 5 | -9 | -6 | -6 | N/A |
| 12/31/2023 | 5 | -9 | -6 | -6 | N/A |
| 9/30/2023 | 4 | -9 | -9 | -8 | N/A |
| 6/30/2023 | 3 | -9 | -11 | -11 | N/A |
| 3/31/2023 | 3 | -9 | -11 | -11 | N/A |
| 12/31/2022 | 2 | -9 | -11 | -11 | N/A |
| 9/30/2022 | 2 | -8 | -10 | -9 | N/A |
| 6/30/2022 | 1 | -7 | -8 | -8 | N/A |
| 3/31/2022 | 1 | -7 | -7 | -7 | N/A |
| 12/31/2021 | 1 | -6 | -6 | -5 | N/A |
| 9/30/2021 | 1 | -5 | -4 | -4 | N/A |
| 6/30/2021 | 1 | -5 | -3 | -3 | N/A |
| 3/31/2021 | 2 | -4 | -3 | -2 | N/A |
| 12/31/2020 | 2 | -3 | -2 | -2 | N/A |
| 12/31/2019 | 2 | -2 | 0 | 0 | N/A |
| 5/31/2019 | 1 | -2 | -3 | -3 | N/A |
| 5/31/2018 | 1 | -1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AREC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AREC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AREC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AREC's revenue (35.2% per year) is forecast to grow faster than the UK market (3.6% per year).
High Growth Revenue: AREC's revenue (35.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AREC's Return on Equity is forecast to be high in 3 years time